✦ LIBER ✦

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

✍ Scribed by Gregorc, Vanesa; Novello, Silvia; Lazzari, Chiara; Barni, Sandro; Aieta, Michele; Mencoboni, Manlio; Grossi, Francesco; Pas, Tommaso De; de Marinis, Filippo; Bearz, Alessandra; Floriani, Irene; Torri, Valter; Bulotta, Alessandra; Cattaneo, Angela; Grigorieva, Julia; Tsypin, Maxim; Roder, Joanna; Doglioni, Claudio; Levra, Matteo Giaj; Petrelli, Fausto; Foti, Silvia; Viganò, Mariagrazia; Bachi, Angela; Roder, Heinrich

Book ID: 122150935
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 280 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70162-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

First-line erlotinib in patients with ad

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

✍ Siow Ming Lee; Iftekhar Khan; Sunil Upadhyay; Conrad Lewanski; Stephen Falk; Ger 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 314 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB

Randomized Phase II Trial of Erlotinib o

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2

✍ Lilenbaum, R.; Axelrod, R.; Thomas, S.; Dowlati, A.; Seigel, L.; Albert, D.; Wit 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Nested Case Control Study of Proteomic B

Nested Case Control Study of Proteomic Biomarkers for Interstitial Lung Disease in Japanese Patients With Non–Small-Cell Lung Cancer Treated With Erlotinib: A Multicenter Phase IV Study (JO21661)

✍ Atagi, Shinji; Katakami, Nobuyuki; Yoshioka, Hiroshige; Fukuoka, Masahiro; Kudoh 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 976 KB

Afatinib versus placebo for patients wit

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

✍ Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; San 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 373 KB